

# Extreme Drug Tolerance of *Mycobacterium tuberculosis*

Antimicrobial Agents and Chemotherapy

62,

DOI: [10.1128/aac.02266-17](https://doi.org/10.1128/aac.02266-17)

Citation Report

#	ARTICLE	IF	CITATIONS
1	NTM drug discovery: status, gaps and the way forward. <i>Drug Discovery Today</i> , 2018, 23, 1502-1519.	3.2	186
2	Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model. <i>Journal of Theoretical Biology</i> , 2018, 446, 87-100.	0.8	23
3	The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2667-2674.	1.3	17
4	Novel Screen to Assess Bactericidal Activity of Compounds Against Non-replicating Mycobacterium abscessus. <i>Frontiers in Microbiology</i> , 2018, 9, 2417.	1.5	26
5	The End of the Binary Era: Revisiting the Spectrum of Tuberculosis. <i>Journal of Immunology</i> , 2018, 201, 2541-2548.	0.4	103
6	Activity of DNA-targeted C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions. <i>Journal of Antibiotics</i> , 2018, 71, 831-834.	1.0	3
7	Clofazimine: A useful antibiotic for drug-resistant tuberculosis. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 1353-1359.	2.5	48
8	Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 93-100.	2.8	33
9	Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development. <i>IUBMB Life</i> , 2018, 70, 926-937.	1.5	27
10	Is IQG-607 a Potential Metallo drug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?. <i>Frontiers in Microbiology</i> , 2018, 9, 880.	1.5	10
11	Impact of immunopathology on the antituberculous activity of pyrazinamide. <i>Journal of Experimental Medicine</i> , 2018, 215, 1975-1986.	4.2	29
12	Advanced cellular systems to study tuberculosis treatment. <i>Current Opinion in Pharmacology</i> , 2018, 42, 16-21.	1.7	7
13	The present state of the tuberculosis drug development pipeline. <i>Current Opinion in Pharmacology</i> , 2018, 42, 81-94.	1.7	70
14	Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1322-1330.	2.5	46
15	Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 615-618.	1.5	6
16	Targeting drugs for tuberculosis. <i>Science</i> , 2019, 364, 1234-1235.	6.0	7
17	Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	76
18	Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 930-940.	4.0	35

#	ARTICLE	IF	CITATIONS
19	Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures. Tuberculosis, 2019, 117, 7-17.	0.8	15
20	Rv0518, a nutritive stress inducible GDSL lipase of Mycobacterium tuberculosis, enhanced intracellular survival of bacteria by cell wall modulation. International Journal of Biological Macromolecules, 2019, 135, 180-195.	3.6	21
21	Repositioning rifamycins for Mycobacterium abscessus lung disease. Expert Opinion on Drug Discovery, 2019, 14, 867-878.	2.5	49
22	Evolution of rifampicin treatment for tuberculosis. Infection, Genetics and Evolution, 2019, 74, 103937.	1.0	61
23	Resistance Reversed in KatG Mutants of Mycobacterium tuberculosis. Trends in Microbiology, 2019, 27, 655-656.	3.5	3
24	The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	13
25	Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	42
26	Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. Drug Metabolism and Disposition, 2019, 47, 665-672.	1.7	31
27	Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	23
28	Tuberculosis drugs™ distribution and emergence of resistance in patient™s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Medicine, 2019, 16, e1002773.	3.9	139
29	Foam Cells: One Size Doesn™t Fit All. Trends in Immunology, 2019, 40, 1163-1179.	2.9	96
30	A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	14
31	The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis. Molecular Biology and Evolution, 2020, 37, 195-207.	3.5	33
32	<i>In vitro</i> drug discovery models for <i>Mycobacterium tuberculosis</i> relevant for host infection. Expert Opinion on Drug Discovery, 2020, 15, 349-358.	2.5	43
33	Bioorthogonal Correlative Light-Electron Microscopy of <i>Mycobacterium tuberculosis</i> in Macrophages Reveals the Effect of Antituberculosis Drugs on Subcellular Bacterial Distribution. ACS Central Science, 2020, 6, 1997-2007.	5.3	15
34	Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis. Clinical Microbiology Reviews, 2020, 34, .	5.7	66
35	Differentially culturable tubercle bacteria dynamics during standard anti-tuberculosis treatment: A prospective cohort study. Tuberculosis, 2020, 124, 101945.	0.8	5
36	Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. Frontiers in Chemistry, 2020, 8, 586294.	1.8	21

#	ARTICLE	IF	CITATIONS
37	Tolerance and Persistence to Drugs: A Main Challenge in the Fight Against Mycobacterium tuberculosis. <i>Frontiers in Microbiology</i> , 2020, 11, 1924.	1.5	32
38	Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis. <i>PLoS Computational Biology</i> , 2020, 16, e1008107.	1.5	21
39	Transcriptional portrait of <i>M. bovis</i> BCG during biofilm production shows genes differentially expressed during intercellular aggregation and substrate attachment. <i>Scientific Reports</i> , 2020, 10, 12578.	1.6	12
40	The within-host evolution of antimicrobial resistance in <i>Mycobacterium tuberculosis</i> . <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	23
41	Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Pharmacology</i> , 2020, 11, 724.	1.6	6
42	Recent Developments in the Application of Flow Cytometry to Advance our Understanding of <i>Mycobacterium tuberculosis</i> Physiology and Pathogenesis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 683-693.	1.1	11
43	Combination antituberculosis therapy: Opportunities and challenges to combat drug-resistant tuberculosis. , 2020, , 111-127.		0
44	Drug-Resistant Tuberculosis 2020: Where We Stand. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2153.	1.3	46
45	Caseum: a Niche for <i>Mycobacterium tuberculosis</i> Drug-Tolerant Persisters. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	63
46	Foam Cells Control <i>Mycobacterium tuberculosis</i> Infection. <i>Frontiers in Microbiology</i> , 2020, 11, 1394.	1.5	28
47	Biology of antimicrobial resistance and approaches to combat it. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	99
48	The quest for the holy grail: new antitubercular chemical entities, targets and strategies. <i>Drug Discovery Today</i> , 2020, 25, 772-780.	3.2	43
49	Both Pharmacokinetic Variability and Granuloma Heterogeneity Impact the Ability of the First-Line Antibiotics to Sterilize Tuberculosis Granulomas. <i>Frontiers in Pharmacology</i> , 2020, 11, 333.	1.6	26
50	Heterogeneous Host-Pathogen Encounters Coordinate Antibiotic Resilience in <i>Mycobacterium tuberculosis</i> . <i>Trends in Microbiology</i> , 2021, 29, 606-620.	3.5	10
51	Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 495-516.	4.2	30
52	Phosphorylation on PstP Regulates Cell Wall Metabolism and Antibiotic Tolerance in <i>Mycobacterium smegmatis</i> . <i>Journal of Bacteriology</i> , 2021, 203, .	1.0	6
54	Metabolic labeling probes for interrogation of the host-pathogen interaction. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 2856-2870.	1.5	10
57	Three-dimensional low shear culture of <i>Mycobacterium bovis</i> BCG induces biofilm formation and antimicrobial drug tolerance. <i>Npj Biofilms and Microbiomes</i> , 2021, 7, 12.	2.9	8

#	ARTICLE	IF	CITATIONS
58	Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes. <i>Mediators of Inflammation</i> , 2021, 2021, 1-13.	1.4	19
59	One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 613149.	1.8	17
60	A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs. <i>Scientific Reports</i> , 2021, 11, 5643.	1.6	15
61	A non-canonical type 2 immune response coordinates tuberculous granuloma formation and epithelialization. <i>Cell</i> , 2021, 184, 1757-1774.e14.	13.5	63
62	<i>Mycobacterium tuberculosis</i> precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. <i>Nature Communications</i> , 2021, 12, 2899.	5.8	38
63	Bacteriostatic Potential of Melatonin: Therapeutic Standing and Mechanistic Insights. <i>Frontiers in Immunology</i> , 2021, 12, 683879.	2.2	25
64	Surface-Shaving Proteomics of <i>Mycobacterium marinum</i> Identifies Biofilm Subtype-Specific Changes Affecting Virulence, Tolerance, and Persistence. <i>MSystems</i> , 2021, 6, e0050021.	1.7	7
66	Rifampicinâ€“Liposomes for <i>Mycobacterium abscessus</i> Infection Treatment: Intracellular Uptake and Antibacterial Activity Evaluation. <i>Pharmaceutics</i> , 2021, 13, 1070.	2.0	13
67	Adjunctive surgery versus medical treatment among patients with cavitary multidrug-resistant tuberculosis. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 1279-1285.	0.6	6
68	Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0058321.	1.4	33
69	Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. <i>Cell Systems</i> , 2021, 12, 1046-1063.e7.	2.9	31
70	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0002421.	1.4	12
71	Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0097821.	1.4	13
72	Exploring the Use of Medicinal Plants and Their Bioactive Derivatives as Alveolar NLRP3 Inflammasome Regulators during <i>Mycobacterium tuberculosis</i> Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9497.	1.8	2
73	Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0050621.	1.4	12
74	The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery. <i>RSC Chemical Biology</i> , 2021, 2, 423-440.	2.0	9
75	Hostâ€“Pathogen Interactions Influencing <i>Mycobacterium tuberculosis</i> Persistence and Drug Tolerance. , 2019, , 217-245.		1
76	Antibacterial medicinal chemistry â€“ what can we design for?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1005-1013.	2.5	4

#	ARTICLE	IF	CITATIONS
77	PerSort Facilitates Characterization and Elimination of Persister Subpopulation in Mycobacteria. MSystems, 2020, 5, .	1.7	12
78	Antibiotic chemotherapy against heterogeneous pathogen populations in complex host tissues. F1000Research, 2019, 8, 1781.	0.8	9
79	Characterization and Elimination of Stochastically Generated Persister Subpopulation in Mycobacteria. SSRN Electronic Journal, 0, , .	0.4	2
80	High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types. ELife, 2018, 7, .	2.8	45
81	On-Slide Heat Sterilization Enables Mass Spectrometry Imaging of Tissue Infected with High-Threat Pathogens Outside of Biocontainment: A Study Directed at <i>Mycobacterium tuberculosis</i> . Journal of the American Society for Mass Spectrometry, 2021, 32, 2664-2674.	1.2	6
85	Consequential drug combinations for tuberculosis treatments. Cell Systems, 2021, 12, 1021-1022.	2.9	0
86	The Role of Fatty Acid Metabolism in Drug Tolerance of Mycobacterium tuberculosis. MBio, 2022, 13, e0355921.	1.8	16
87	Bugs on Drugs: A Drosophila melanogaster Gut Model to Study In Vivo Antibiotic Tolerance of E. coli. Microorganisms, 2022, 10, 119.	1.6	5
88	The Tuberculous Granuloma and Preexisting Immunity. Annual Review of Immunology, 2022, 40, 589-614.	9.5	32
89	Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. International Journal of Antimicrobial Agents, 2022, 59, 106509.	1.1	6
90	Transcriptome signature of cell viability predicts drug response and drug interaction in Mycobacterium tuberculosis. Cell Reports Methods, 2021, 1, 100123.	1.4	4
91	Drug concentration at the site of disease in children with pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1710-1719.	1.3	3
92	Mycobacterial quorum quenching and biofilm inhibition potential of medicinal plants. , 2022, , 309-333.		0
93	Identification of $\beta$ -Lactams Active against <i>Mycobacterium tuberculosis</i> by a Consortium of Pharmaceutical Companies and Academic Institutions. ACS Infectious Diseases, 2022, 8, 557-573.	1.8	13
95	Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy. PLoS Pathogens, 2022, 18, e1010459.	2.1	21
96	In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses. Frontiers in Immunology, 2022, 13, 820134.	2.2	19
98	Types and functions of heterogeneity in mycobacteria. Nature Reviews Microbiology, 2022, 20, 529-541.	13.6	19
99	Quantitative prediction of conditional vulnerabilities in regulatory and metabolic networks using PRIME. Npj Systems Biology and Applications, 2021, 7, 43.	1.4	3

#	ARTICLE	IF	CITATIONS
100	Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0158821.	1.4	2
101	Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab660.	0.4	6
102	Antituberculosis Drug Repurposing: A New Hope for Tackling Multi-Challenging TB in Timely Manner. , O, , .		1
105	CinA mediates multidrug tolerance in <i>Mycobacterium tuberculosis</i> . <i>Nature Communications</i> , 2022, 13, 2203.	5.8	22
106	<i>Borrelia burgdorferi</i> Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes. <i>MBio</i> , 2022, 13, e0344021.	1.8	14
107	Anti-tuberculosis treatment strategies and drug development: challenges and priorities. <i>Nature Reviews Microbiology</i> , 2022, 20, 685-701.	13.6	142
108	In vitro activity of rifabutin against <i>Mycobacterium abscessus</i> , clinical isolates. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2022, 49, 767-775.	0.9	2
109	Tuberculosis Drug Discovery: Challenges and New Horizons. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7489-7531.	2.9	59
110	<i>Mycobacterium</i> serine/threonine phosphatase <i>PstP</i> is phosphoregulated and localized to mediate control of cell wall metabolism. <i>Molecular Microbiology</i> , 2022, 118, 47-60.	1.2	5
111	A high content screening assay for discovery of antimycobacterial compounds based on primary human macrophages infected with virulent <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2022, 135, 102222.	0.8	3
112	Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	4
113	C25-modified rifamycin derivatives with improved activity against <i>Mycobacterium abscessus</i> . , 2022, 1, .		6
114	Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13240-13252.	2.9	8
115	Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	26
116	Phenotypic adaptation of <i>Mycobacterium tuberculosis</i> to host-associated stressors that induce persister formation. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
117	The evolving biology of <i>Mycobacterium tuberculosis</i> drug resistance. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	6
118	<i>Mycobacterium tuberculosis</i> functional genetic diversity, altered drug sensitivity, and precision medicine. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
119	Tools to Alleviate the Drug Resistance in <i>Mycobacterium tuberculosis</i> . <i>Molecules</i> , 2022, 27, 6985.	1.7	1

#	ARTICLE	IF	CITATIONS
120	Redesign of Rifamycin Antibiotics to Overcome ADP-Dependent Ribosylation-Mediated Resistance. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	9
121	Redesign of Rifamycin Antibiotics to Overcome ADP-Dependent Ribosylation-Mediated Resistance. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	2
122	Microfluidic dose-response platform to track the dynamics of drug response in single mycobacterial cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
125	SigH stress response mediates killing of <i>Mycobacterium tuberculosis</i> by activating nitronaphthofuran prodrugs via induction of Mrx2 expression. <i>Nucleic Acids Research</i> , 0, , .	6.5	0
126	<i>Mycobacterium tuberculosis</i> Requires the Outer Membrane Lipid Phthiocerol Dimycocerosate for Starvation-Induced Antibiotic Tolerance. <i>MSystems</i> , 2023, 8, .	1.7	5
127	The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy. <i>ELife</i> , 0, 12, .	2.8	2
128	Tools to develop antibiotic combinations that target drug tolerance in <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
129	Adaptation to the intracellular environment of primary human macrophages influences drug susceptibility of <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2023, 139, 102318.	0.8	1
130	A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant <i>M. tuberculosis</i> found in Caseum. <i>MBio</i> , 2023, 14, .	1.8	4
133	Multiomics Integration of Tuberculosis Pathogenesis. <i>Integrated Science</i> , 2023, , 937-967.	0.1	0
144	Revolutionizing control strategies against <i>Mycobacterium tuberculosis</i> infection through selected targeting of lipid metabolism. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	2
145	Tuberculosis: Experimental Models, Innovations, and Challenges. , 2023, , 669-712.		0